Posted by Michael Wonder on 06 Mar 2018
Agency for 7 March TC meeting
6 March 2018 - HAS has posted the agenda for the next scheduled TC meeting.
The Transparency Commission will consider the reimbursement of:
- Obinutuzumab (Gazyvaro)
- Brodalumab (Kyntheum)
- Budesonide (Entocort)
